Rescreening Gets A Boost
Executive Summary
As Pap smear technology advances, lines are being drawn in the sand between product companies and their pathologist and physician customers. Neuromedical Systems' aggressive consumer marketing campaign warned women that Pap smears alone aren't enough to accurately diagnose cervical cancer, that the company's new rescreening technology. But physicians are up in arms, concerned that the company is getting them into potential liability troubles if they don't rescreeen.You may also be interested in...
Viatris Will Tread A Different Path
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
EU Single Patent System On Course For 2020
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
Internal Manufacturing Capabilities Are Critical To Level-Up eTheRNA
A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports